Einige Inhalte dieser Anwendung sind momentan nicht verfügbar.
Wenn diese Situation weiterhin besteht, kontaktieren Sie uns bitte unterFeedback&Kontakt
1. (WO2004093688) METHOD FOR TREATMENT OF ISCHAEMIC TISSUE
Anmerkung: Text basiert auf automatischer optischer Zeichenerkennung (OCR). Verwenden Sie bitte aus rechtlichen Gründen die PDF-Version.

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A method for treating ischaemic tissue comprising
cutting the tissue to form a wound;
- providing a sponge-like element, the element being structured to receive blood and to comply with the
movement of the tissue;
locating the element in the wound and in contact with a source of blood whereby the element receives blood from the source of blood to thereby promote tissue growth and angiogenesis throughout and beyond the element.

2. A method according to claim 1 wherein the element has the compliance of a polyurethrane .

3. The method according to claim 1 or 2 wherein the source of blood is the wound.

4. The method according to any one of claims 1 to 3 wherein the sponge-like element has a pore size of between 50 and 200 microns in diameter.

5. The method according to any one of claims 1 to 4 wherein the sponge-like element has a pore space of
between 50% and 90% of the total volume of the element.

6. The method according to any one of claims 1 to 5 wherein the sponge-like element comprises a recess.

7. The method of claim 6 wherein the recess extends along a substantial portion of the length of the element.

8. A method according to any one of claims 1 to 7 wherein the element comprises a compound selected from the group consisting of: polyether urethane, a polyether urethane urea, a polyether carbonate urethane, a polyether carbonate urethane urea, a polycarbonate urethane, a polycarbonate urethane urea, polycarbonate silicone urethane, a polycarbonate silicone urethane urea, a polydimethylsiloxane urethane, a polydimethylsiloxane urethane urea, a polyester urethane, a polyester urethane urea, pellethane, chronoflex, hydrothane, estane, Elast-Econ, Texin, Biomer type polyurethanes, Surethane,
Corethane, Carbonate, Techoflex, Techothane and Biospan, elastin, tropoelastin, collagen, starch, fibrin,
polyhydroxyalkanoate, poly (1, 3-trimethylene carbonates, tofu, caprolactone-co-L-Lactide, poly-L-lactide,
poly (glycerol-sebacate) , or mixtures thereof.

9. A method according to any one of claims 1 to 8 wherein the wound is formed in ischaemic tissue.

10. A method according to any one of claims 1 to 8 wherein the wound is formed in infarcted tissue.

11. A method according to any one of claims 1 to 8 wherein the wound is formed in fibrotic tissue or scar tissue.

12. A method according to any one of claims 1 to 8 wherein the wound is formed in ventricular tissue.

13. A method according to any one of claims 1 to 12 wherein the tissue is cut to form the wound by incising the tissue.

14. A method according to claim 13 wherein the tissue is incised by a laser.

15. A method according to any one of claims 1 to 14 wherein the element further comprises at least one agent for controlling growth of tissue and angiogenesis
throughout and beyond the element.

16. A method according to claim 15 wherein the agent controls regeneration of the tissue.

17. A method according to claim 15 wherein the agent promotes or stimulates regeneration of the tissue.

18. A method according to claim 15 wherein the agent is selected from the group consisting of: epidermal growth factor agonists, transforming growth factor-beta
antagonists (1,2 and 3), platelet-derived growth factor antagonists, Angiotensin converting enzyme (ACE) , Ang II receptor antagonists [such as ATI (losartan) or AT2
(PD123177) ], inhibitors of plasminogen activators,
inhibitors of matrix metalloproteinases, inhibitors of collagen prolyl hydroxylase, inhibitors of urokinase-type plasminogen activator, Bradykinin B2 receptor antagonists (for example, Hoel40) , inhibitors of cyclooxygenase (for example, indomethacin) , calmodulin antagonists,
anesthetics such as lidocaine and pentobarbital, inhibitors of polymorphonuclear leukocyte elastase and inhibitors of leukocyte migration or mixtures thereof.

19. A method according to any one of claims 1 to 18 wherein the element further comprises at least one species of cell for growth of tissue and angiogenesis throughout and beyond the element.

20. A method according to claim 19 wherein the cell is selected from the group consisting of: endothelial cells, smooth muscle cells, skeletal muscle cells, pericytes, embryonic stem cells, stem cells, cultured myocytes or precursors of cardiomyocytes, myofibroblasts, fibroblasts and cells expressing proteins to promote angiogenesis or cell growth.

21. A method according to any one of claims 1 to 20 wherein the element further comprises at least one agent for controlling angiogenesis throughout the element.

22. A method according to claim 21 wherein the agent is selected from the group consisting of: IGF, TGF-α, TGF-β,

VEGF, FGF, β-FGF, GAS-6, PDGF, PIGF, CSF, GM-CSF, MCP-1, heparin, warfarin, inhibitors of matrix
metalloproteinases, agonists of matrix metalloproteinases, Simvastatin, nicotinic analogues, nicotinic agonists, nicotinic antagonists, angiopoiten, dopamine analogues, dopamine agonists, dopamine antagonists, other cytokines and serine proteases or mixtures thereof.

23. A method according to any one of claims 1 to 22 wherein the element comprises an agent for attracting cell types to the element.

24. The method according to claim 23 wherein the agent is capable of attracting stem cells or resident satellite cells.

25. The method of claim 23 or 24 wherein the agent is SDF-1 or CXCR-4.

26. A method according to any one of claims 1 to 25 wherein the tissue is muscle tissue.

27. A method according to any one of claims 1 to 25 wherein the tissue is cardiac tissue.

28. A method for treating ischaemic heart disease
comprising:
cutting ventricular or septal cardiac tissue to form a wound;
providing a sponge-like element, the element being structured to receive blood and to comply with the
movement of the tissue;
locating the element in the wound and in contact with a source of blood whereby the element receives blood from the source of blood to thereby promote tissue growth and angiogenesis throughout and beyond the element.

29. A method for treating myocardial infarction
comprising:
cutting ventricular or septal cardiac tissue to form a wound;
- providing a sponge-like element, the element being structured to receive blood and to comply with the
movement of the tissue;

locating the element in the wound and in contact with a source of blood whereby the element receives blood from the source of blood to thereby promote tissue growth and angiogenesis throughout and beyond the element.

30. A method for promoting or stimulating angiogenesis in ischaemic tissue comprising:
cutting non-ischaemic tissue that is adjacent
ischaemic tissue to form a wound;
- providing a sponge-like element, the element being structured to receive blood and to comply with the
movement of the tissue;
locating the element in the wound and in contact with a source of blood whereby the element receives blood from the source of blood to thereby promote tissue growth and angiogenesis throughout and beyond the element and into the ischaemic tissue.

31. A method for promoting or stimulating angiogenesis in ischaemic heart tissue comprising:
cutting ischaemic tissue to form a wound in
communication with the ventricular cavity;
providing a sponge-like element, the element being structured to receive blood and to comply with the
movement of the tissue;
locating the element in the wound and in
communication with the ventricular cavity whereby the element receives blood from the ventricular cavity to thereby promote tissue growth and angiogenesis throughout and beyond the element and into the ischaemic tissue.

32. Use of a sponge-like element according to the method of any one of claims 1 to 31.

33. A sponge-like element when used according to the method of any one of claims 1 to 31.

34. A method for treating ischaemic tissue substantially as hereinbefore described with reference to the Figures.